← Back to Search

2'-fucosyllactose for Weight Loss (HMO-RCT Trial)

N/A
Waitlist Available
Research Sponsored by Advanced Protein Technologies Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (0 weeks), midpoint (6 weeks), and endpoint (12 weeks)
Awards & highlights

Summary

A randomized, double-blind, placebo-controlled, parallel arm study of 2'-fucosyllactose (2'-FL) was conducted in healthy males and females between the ages of 18 and 65 at the time of consent. 2'-FL is one of the most prominent HMOs in human milk. Preclinical studies indicate that 2'-FL feeding is prebiotic, anti-inflammatory, anti-thrombotic, and may reduce skeletal muscle atrophy during energy restriction. The investigators hypothesize that supplementation of 2'-FL affects the preservation of muscle mass, strength, and markers of health during exercise and a hypo-energetic weight loss program. To test this hypothesis, the investigators will compare 3 g/day of 2'-FL with 3 g/day of maltodextrin placebo as a daily supplement.

Eligible Conditions
  • Weight Loss

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (0 weeks), midpoint (6 weeks), and endpoint (12 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (0 weeks), midpoint (6 weeks), and endpoint (12 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Body Fat
Change in Body Height
Change in Body Mass Index (BMI)
+6 more
Secondary study objectives
Change in Aerobic Capacity
Change in Hemoglobin
Change in Red Blood cell
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: 2'-fucosyllactoseExperimental Treatment1 Intervention
3 g/day of 2'-FL powder orally once daily for 12 weeks
Group II: MaltodextrinPlacebo Group1 Intervention
3 g/day of banana-flavored maltodextrin powder orally once daily for 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
2'-Fucosyllactose
2023
N/A
~60

Find a Location

Who is running the clinical trial?

Advanced Protein Technologies CorporationLead Sponsor
Richard B Kreider, ProfessorStudy Directorrbkreider@tamu.edu
~26 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top